Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well alpelisib works in treating participants with human
papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by
surgery. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.